In vitro simian virus 40 large tumor antigen expression correlates with differential immune responses following DNA immunization.

In vitro simian virus 40 large tumor antigen expression correlates with differential immune responses following DNA immunization.
复制标题

体外猿猴病毒 40 大肿瘤抗原表达与 DNA 免疫后的差异免疫反应相关。

DOI:
10.1016/j.virol.2004.08.041
复制
发表时间:
2005
期刊:
Virology.
影响因子:
--
通讯作者:
Kennedy,RonaldC
Kennedy,RonaldC
中科院分区:
--
文献类型:
--
作者:
Lowe,DevinB;Shearer,MichaelH;Tarbox,JamesA;Kang,HyunSeok;Jumper,CynthiaA;Bright,RobertK;Kennedy,RonaldC

文献摘要

参考文献

被引文献

相似文献

猴病毒40(SV 40)含有一种必需蛋白,即大肿瘤抗原(Tag),它有助于病毒复制并引起细胞转化和永生化。我们的实验室已经检查了质粒DNA,表达SV 40标签下两个不同的启动子,用于潜在的癌症疫苗接种策略。一个质粒,pSV 3-neo,未能诱导SV 40标签抗体,产生弱的细胞介导的反应,在小鼠实验肿瘤攻击系统中只有部分保护。第二个质粒pCMV-Tag诱导了针对SV 40 Tag的抗体,产生了强大的细胞介导的应答,并在体内引起了完全的肿瘤免疫。质粒DNA免疫和肿瘤细胞攻击后诱导的CD 4+和CD 8 + T细胞应答反映了1型细胞因子分泌谱。我们对这种差异性免疫应答的假设是,pCMV-标签由于更有效的启动子而表现出更高水平的转基因表达。我们确定,与pSV 3-neo相比,pCMV-Tag的SV 40 Tag mRNA和蛋白表达水平更高。可能需要阈值量的SV 40标签来刺激抗体产生并提供完全的全身肿瘤免疫。
Simian virus 40 (SV40) contains an essential protein, large tumor antigen (Tag), which assists in viral replication and causes cell transformation and immortalization. Our laboratory has examined plasmid DNA, expressing SV40 Tag under two different promoters, for use in potential cancer vaccination strategies. One plasmid, pSV3-neo, failed to induce SV40 Tag antibody, produced a weak cell-mediated response, and only partial protection in murine experimental tumor challenge systems. The second plasmid, pCMV-Tag, induced antibodies to SV40 Tag, produced a robust cell-mediated response, and invoked complete tumor immunity in vivo. The induction of CD4+ and CD8+ T cell responses following plasmid DNA immunization and tumor cell challenge reflected a type 1 cytokine secretion profile. Our hypothesis for this differential immune response is that pCMV-Tag exhibits a higher level of transgene expression due to a more efficient promoter. We determined that pCMV-Tag levels of SV40 Tag mRNA and protein expression were higher when compared to pSV3-neo. A threshold amount of SV40 Tag may be required to stimulate antibody production and provide complete systemic tumor immunity.
治疗癌症的 DNA 疫苗策略。
DOI: --
发表时间: 1998
影响因子: --
作者:
P. Benton;R. Kennedy
通讯作者: R. Kennedy
用重组SV40大肿瘤抗原和单克隆抗独特型免疫小鼠的体液免疫反应和肿瘤免疫的比较。
DOI: --
发表时间: 1993
期刊: Cancer Research
影响因子: 11.2
作者:
M. Shearer;R. K. Bright;R. Kennedy
通讯作者: R. Kennedy
重组猿病毒40大肿瘤抗原的小鼠体液免疫应答比较:表位特异性和独特型表达
DOI: --
发表时间: 1993
期刊: Cancer Immunology and Immunotherapy
影响因子: --
作者:
R. K. Bright;M. Shearer;R. Kennedy
通讯作者: R. Kennedy
DOI: 10.1016/s0264-410x(99)00569-1
发表时间: 2000-05-22
期刊: VACCINE
影响因子: 5.5
作者:
Galvin, TA;Muller, J;Khan, AS
通讯作者: Khan, AS
小鼠抗体对 HIV-1 gp160 反应的精细特异性由定义选定表位的合成肽决定。
DOI: 10.1016/0161-5890(92)90138-n
发表时间: 1992
影响因子: 3.6
作者:
Wolf,H;Warren,RQ;Stunz,GW;Shuler,KR;Kanda,P;Kennedy,RC
通讯作者: Kennedy,RC